HSK21542
Phase 3Small molecule
Haisco Pharmaceutical Group Co., Ltd.HSK21542 is one of 50 small molecule programs targeting Chemotherapy-induced nausea and vomiting. It is currently in Phase 3.
2
Indications
14
Total Trials
2
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
78 competitors in Nausea and Vomiting
#DrugCompanyPhaseTrials
1Robinul
Jazz PharmaceuticalsApproved
Olinvyk
TTrevena Inc.
Approved
Thalomid
Bristol-Myers SquibbPhase 3
Megace
Bristol-Myers SquibbPhase 3
Gemzar
Johnson & JohnsonPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Nereus
VVanda Pharmaceuticals
Phase 3
Qbrexza
PPeking Union Medical College Hospital
Approved
HSK21542
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Adriamycin
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Tics2 trials
Renal Impairment1 trial
Chemotherapy-induced nausea and vomiting1 trial
Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT06593782·180 enrolled
7 more indications
Metabolism1 trial
Postoperative Analgesia1 trial
Nausea and vomiting1 trial
Liver Disease1 trial
Chronic Kidney Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HSK21542. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details